Our current study showed that low dose IL-2 treatment protected 50% mice from diabetes after STZ injection, which is a promising result but is not optimal when considering other treatment like IL-35 provided almost complete protection in STZ mice [14, 26]. This evidence concerns the gene IL2 and diabetes mellitus.